Management

 
Roger D. Tung, Ph.D.
Co-Founder, President and CEO
Roger D. Tung, Ph.D.

Roger D. Tung, Ph.D. is our scientific founder and has served as our President and Chief Executive Officer and as a member of our board of directors since April 2006. Before Concert, Dr. Tung was a founding scientist at Vertex, a pharmaceutical company, where he was employed from 1989 to 2005, most recently as its Vice President of Drug Discovery. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare provider, and The Squibb Institute for Medicinal Chemistry. During his career, Dr. Tung has overseen the discovery of five drugs approved for the treatment of HIV, hepatitis C, and cystic fibrosis and was an inventor of several of them. He also serves as a member of the University of Wisconsin-Madison School of Pharmacy’s Board of Visitors, faculty mentor in the MIT IMPACT program, and strategic advisor to Longwood Founder’s Fund. Dr. Tung received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison.

 
Marc Becker
Chief Financial Officer
Marc Becker

Mr. Marc Becker has served as our Chief Financial Officer since January 2018. Prior to joining Concert, Mr. Becker served as Senior Vice President and Chief Financial Officer at CRISPR Therapeutics from February 2016 to September 2017. Prior to joining CRISPR Therapeutics, Mr. Becker served as Chief Financial Officer and Senior Vice President of rEVO Biologics, a biopharmaceutical company, from January 2012 to February 2016. Before rEVO, Mr. Becker spent 10 years at Genzyme Corporation, most recently serving as Finance Director for the UK and Ireland before returning to the United States to become the Vice President of Finance for Genzyme’s Renal and Endocrine business. He also serves on the Board of Directors of Food for Free, a non-profit organization in Cambridge, MA. Mr. Becker began his career in auditing and commercial lending for financial services firms, KPMG and BankBoston. Mr. Becker holds a BS from the University of Massachusetts, an MBA from Babson College and was licensed as a CPA.

 
James V. Cassella, Ph.D.
Chief Development Officer
James V. Cassella, Ph.D.

Dr. James V. Cassella has served as our Chief Development Officer since February 2015. Prior to joining Concert, Dr. Cassella had senior level roles in biopharmaceutical companies, including Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from June 2004 to January 2015. Prior to Alexza Pharmaceuticals, Dr. Cassella held various management positions at Neurogen Corporation, including Senior Vice President, Clinical Research and Development. Before joining the biotechnology industry, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received his Ph.D. in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in psychology from the University of New Haven.

 
Jeffrey A. Munsie
Chief Legal Officer
Jeffrey A. Munsie

Mr. Jeffrey A. Munsie has served as our Chief Legal Officer since September 2019. Prior to joining Concert Mr. Munsie served as Senior Vice President, General Counsel and Head of Corporate Operations at Merrimack Pharmaceuticals, a biopharmaceutical company, from 2011 to 2019. Prior to Merrimack, he was a member of the corporate department at the law firm Wilmer Cutler Pickering Hale and Dorr in Boston from 2002 to 2011. Mr. Munsie received a J.D. from Harvard Law School and a B.A. from Dartmouth College.

 
Nancy Stuart
Chief Operating Officer
Nancy Stuart

Ms. Nancy Stuart has served as our Chief Operating Officer since October 2007 and was our Senior Vice President, Corporate Strategy and Operations from July 2006 to October 2007. Prior to joining Concert Ms. Stuart held various business operations and business development positions at Amgen Inc., a biopharmaceutical company, Kinetix Pharmaceuticals, Inc., a pharmaceutical company subsequently acquired by Amgen, Vertex, a pharmaceutical company and Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A. She also serves on the Board of Directors of The Greater Boston YMCA. Ms. Stuart holds a B.S. from the University of Michigan, and an M.B.A. from the Simmons College Graduate School of Management.

 
Justine E. Koenigsberg
Senior Vice President, Corporate Communications and Investor Relations
Justine E. Koenigsberg

Ms. Justine Koenigsberg joined Concert in March 2008 and currently serves as Senior Vice President, Corporate Communications and Investor Relations. She has more than 22 years corporate communications and investor relations experience within the biotechnology industry. Prior to joining Concert she held senior communication roles at ViaCell, Inc. and Transkaryotic Therapies (TKT) where she developed and implemented a variety of communication strategies and managed their investor relations programs. Prior to TKT, she held communications positions at Vertex Pharmaceuticals. Ms. Koenigsberg is a member of the National Investors Relations Institute and served on the Board of Directors and as a Past-President of its Boston Chapter. She holds a B.S. in Business Administration from Northeastern University.

 
Robert Silverman, J.D., Ph.D.
Senior Vice President, Legal Affairs
Robert Silverman, J.D., Ph.D.

Dr. Robert Silverman joined Concert in January 2007 and currently serves as Senior Vice President, Legal Affairs. He was our General Counsel from January 2007 to June 2017. Prior to joining Concert, he served in various legal related roles at Millennium Pharmaceuticals, Inc., Vertex Pharmaceuticals, and FMC Corporation. Dr. Silverman received his J.D. from Rutgers Law School.He began his career as a research chemist after postdoctoral training in organic chemistry at Stanford University. Dr. Silverman received a Ph.D. in organic chemistry from the University of New Mexico and a B.A. from Lehigh University. Since 2012, he has been on the Business Development Fundamentals faculty for BIO.

 
Virginia Braman
Vice President, Clinical Development
Virginia Braman

Ms. Virginia Braman joined Concert in April 2010 and currently serves as Vice President, Clinical Development. She has over 25 years of research, development and clinical experience. Prior to Concert, she had a variety of clinical roles across a number of therapeutic areas at Cambridge BioScience, ImmunoGen, Cardiokine, and NitroMed. At NitroMed, she managed the Phase 3 clinical trial for BiDil® for the treatment of heart failure, which led to FDA approval. Prior to joining the biotechnology industry, Ms. Braman conducted research using monoclonal antibodies at both Beth Israel Hospital in Boston and University of Pennsylvania Medical School. Ms. Braman holds a B.S. in Biology from Northeastern University.

 
Christine Boisclair
Vice President, Regulatory Affairs and Quality Assurance
Christine Boisclair

Ms. Christine Boisclair joined Concert in June 2016 as Vice President, Regulatory Affairs and Quality Assurance with more than 30 years Regulatory Affairs experience in the biopharmaceutical industry and across multiple therapeutic areas. Prior to joining Concert, Ms. Boisclair was Vice President, Regulatory Affairs at Forum Pharmaceuticals. Before joining Forum Pharmaceuticals Ms. Boisclair held management roles at several companies including Insmed Inc, Agennix Inc, OSI Pharmaceuticals Inc, Genzyme Corporation, Immulogic Pharmaceuticals and Parexel International. Ms. Boisclair began her regulatory career at Searle Pharmaceuticals and Glaxo in the UK.She received a Bachelor of Science Honors Degree in Biochemistry from the University of York in the United Kingdom.

 
Cameron J. Cowden, Ph.D.
Vice President, Pharmaceutical Development
Cameron J. Cowden, Ph.D.

Dr. Cameron Cowden joined Concert in January 2016 and currently serves as Vice President, Pharmaceutical Development. He has nearly 20 years of process chemistry and chemical engineering experience in the pharmaceutical industry. Prior to joining Concert, Dr. Cowden was an Executive Director in Process Chemistry at Merck. He received his Ph.D. from the University of Melbourne, Australia and was a postdoctoral fellow at Cambridge University in the United Kingdom.

 
Julie Fields Liu, Ph.D.
Vice President, Research and Development Management
Julie Fields Liu, Ph.D.

Dr. Julie Fields Liu joined Concert in January 2007 and currently serves as Vice President, Research and Development Management. She has more than 20 years of experience in the pharmaceutical and biotechnology industry in the fields of medicinal chemistry, research management, and development program management. Prior to joining Concert, Dr. Liu worked at Millennium Pharmaceuticals in the areas of oncology, inflammation, and metabolic disease. She earned her B.S. in Chemistry with honors and distinction from the University of North Carolina at Chapel Hill, and her Ph.D. in Organic Chemistry from the University of California, Berkeley.

Back to Top